Previous 10 | Next 10 |
Pieris Pharmaceuticals PIRS +46% on collaboration with Seagen.Houston Wire & Cable Company HWCC +41% on being acquired by OmniCable for $5.30 per share.Cellect Biotechnology APOP +41% on a definitive merger agreement with Quoin Pharmaceuticals.Immutep Limited...
Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q4 2020 Earnings Call Transcript
MacroGenics, Inc. (MGNX) Q4 2020 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and Chief Executive Officer Jim Karrels - Senior Vice President and Chief Financial Officer Conference Call Participants Ev...
MacroGenics (MGNX): FY GAAP EPS of -$2.47 beats by $0.63.Revenue of $104.88M (+63.4% Y/Y) beats by $28.21M.Press Release For further details see: MacroGenics EPS beats by $0.63, beats on revenue
MARGENZA™ approved in December 2020; commercial launch expected March 2021 July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab Multiple clinical updates across portfolio anticipated in 2021 Conference call scheduled for t...
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its finan...
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica ...
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been...
MGNX has one approved product, and focus is now on its DART platform for developing bispecific antibodies. The early data shows strong potential for flotetuzumab. Their pipeline looks highly diverse and interesting. For further details see: MacroGenics: A Look At The DAR...
We'll take a look at an interesting therapeutic idea involving T-cells and how it's going. For some years now, Amgen has been working on a technology called "BiTE", which stands for "bispecific T-cell engager". It fits into the general "bifunctional molecule" idea that's so popular th...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...